SME Central
Home / Moved to Main Board / Kwality Pharmaceuticals

Kwality Pharmaceuticals: IPO, Share Price and Results Since Listing

Kwality Pharmaceuticals moved from BSE SME to the BSE main board. For Q2 FY2027 it reported revenue of INR 181.22 crore (+63.19% on a year earlier) and a profit after tax of INR 29.03 crore.

Key Facts

Moved to
BSE main board (BSE does not publish the date)
Listed on BSE SME
18 July 2016
Symbol
KPL (BSE code 539997)
Latest close
INR 3,824.45 on 13 November 2026

Results Filed With BSE

Consolidated figures, INR crore. Change compares with the same period a year earlier.

PeriodRevenueChangeProfit after taxEPS (INR)Filed
Q2 FY2027181.22+63.19%29.0327.93after listing12 November 2026
Q1 FY2027162.35+45.63%25.6224.69after listing10 August 2026
Q4 FY2026157.11+35.82%25.3124.39after listing19 May 2026
FY2026503.08+35.90%67.3564.90after listing19 May 2026
Q3 FY2026123.44–1615.42after listing12 February 2026
Q2 FY2026111.05–14.1213.60after listing13 November 2025
Q1 FY2026111.48–11.9211.49after listing11 August 2025
Q4 FY2025115.68–14.4813.95after listing19 May 2025
FY2025370.20–39.8038.36after listing19 May 2025

Promoter Holding

Promoter holding has moved from 54.83% on 31 December 2025 to 54.86% on 30 September 2026 (+0.03 percentage points).

As ofPromotersPublic
30 September 202654.86%45.14%
30 June 202654.86%45.14%
31 March 202654.87%45.13%
31 December 202554.83%45.17%

Sources: BSE filings (results XBRL, shareholding pattern, board meetings), BSE daily price files, and IPO records. Prices are not adjusted for bonus issues or splits.